---
title: "MAZE.US (MAZE.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/MAZE.US/news.md"
symbol: "MAZE.US"
name: "MAZE.US"
parent: "https://longbridge.com/en/quote/MAZE.US.md"
datetime: "2026-03-03T15:09:39.767Z"
locales:
  - [en](https://longbridge.com/en/quote/MAZE.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/MAZE.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/MAZE.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/MAZE.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/MAZE.US/news.md)


# MAZE.US (MAZE.US) — Related News

### [MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation](https://longbridge.com/en/news/277581075.md)
*2026-03-03T07:45:00.000Z*
> MindMaze Therapeutics has provided a corporate update and published its March 2026 investor presentation. CEO Alexandre 

### [Mahzi doses first patient in MZ-1866 trial for Pitt Hopkins syndrome](https://longbridge.com/en/news/277033094.md)
*2026-02-26T11:38:09.000Z*
> Mahzi Therapeutics has initiated its Phase I/II UNITE study by dosing the first patient with MZ-1866, a gene therapy tar

### [09:40 ETMahzi Therapeutics Announces First Patient Dosed in Phase 1/2 UNITE Study of MZ-1866 for Pitt Hopkins Syndrome](https://longbridge.com/en/news/276903873.md)
*2026-02-25T14:40:50.000Z*
> Mahzi Therapeutics Inc. has announced the dosing of the first patient in its Phase 1/2 UNITE study for MZ-1866, an inves

### [Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit](https://longbridge.com/en/news/275972996.md)
*2026-02-14T09:06:18.000Z*
> Maze Therapeutics (NASDAQ: MAZE) is advancing a genetics-driven drug development approach, focusing on kidney and metabo

### [Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock](https://longbridge.com/en/news/274881429.md)
*2026-02-04T23:00:00.000Z*
> Amy Bachrodt, SVP of Maze Therapeutics (NASDAQ:MAZE), sold 5,000 shares at $46.04 each on February 2nd, totaling $230,20

### [Maze Therapeutics Secures Up to $200 Million Term Loan Facility from Hercules Capital](https://longbridge.com/en/news/274873544.md)
*2026-02-04T21:46:22.000Z*
> Maze Therapeutics Inc. has secured a senior secured term loan facility of up to $200 million from Hercules Capital, Inc.

### [Maze Therapeutics President and CMO Harold Bernstein Reports Disposal of Common Shares](https://longbridge.com/en/news/274870273.md)
*2026-02-04T21:26:19.000Z*
> Harold Bernstein, President and CMO of Maze Therapeutics Inc., reported the disposal of common shares of the company. Th

### [Maze Therapeutics to Present at Guggenheim Emerging Outlook: Biotech Summit 2026](https://longbridge.com/en/news/274807478.md)
*2026-02-04T12:00:50.000Z*
> Maze Therapeutics Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026. CEO Ja

### [Maze Therapeutics CSBO Atul Dandekar Reports Disposal of Common Shares](https://longbridge.com/en/news/274559402.md)
*2026-02-02T21:22:17.000Z*
> Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics Inc., has reported the disposal of common shares

### [Strs Ohio Decreases Stake in Maze Therapeutics, Inc. $MAZE](https://longbridge.com/en/news/274423399.md)
*2026-02-01T13:19:14.000Z*
> Strs Ohio reduced its stake in Maze Therapeutics, Inc. (NASDAQ: MAZE) by 61.8% in Q3, now holding 17,900 shares valued a